What Is Dilution in Biotech Stocks?
Dilution happens when a company issues new shares, increasing the total share count. For biotech investors, dilution is one of the most important risks to understand.
Many biotech companies do not generate product revenue for years. They fund operations by issuing stock, warrants, convertible securities or other financing instruments.
Simple example
Imagine an acquirer would pay a fixed $1 billion to buy a biotech. If the company has 100 million shares outstanding, that works out to $10 per share. If the company first issues 50 million new shares, the same $1 billion is now divided across 150 million shares — about $6.67 per share.
The key point is that when you model a fixed takeout value, more shares mean less value per share. This is why dilution directly reduces per-share upside, and why market cap alone can be misleading.
Why biotech companies dilute
Biotech companies raise capital to fund clinical trials, manufacturing, regulatory filings, launch preparation, hiring, research, licensing deals, debt repayment and general corporate purposes.
Dilution is not always bad. If a company raises money at a high stock price and uses it to create value, dilution can be rational. But investors must model it.
Fully diluted share count
Fully diluted share count includes common shares, options, warrants, restricted stock units, convertible securities and other instruments that may become shares. This number matters when modeling buyout value per share.
| Fully diluted shares | $5B value per share |
|---|---|
| 100M | $50.00 |
| 200M | $25.00 |
| 300M | $16.67 |
| 400M | $12.50 |
Common sources of dilution
Common sources include public offerings, ATM offerings, warrants, convertible debt and stock compensation.
Read more: What Is an ATM Offering in Biotech Stocks?
Dilution before catalysts
Biotech companies often raise capital before major catalysts. If a trial fails, raising capital afterward may be much harder. If a trial succeeds, the company may need more money to prepare for commercialization.
What investors should check
Review cash balance, quarterly cash burn, cash runway, shelf registration, ATM facility, warrants, options, RSUs, debt, fully diluted share count and upcoming trial or launch costs.
Frequently asked questions
What is dilution in biotech stocks?
Dilution happens when a company issues new shares, increasing the total share count. Biotech companies dilute often because most do not generate product revenue for years and fund operations by issuing stock, warrants or convertible securities. As the share count rises, each existing share can represent a smaller slice of the company’s value.
Is dilution always bad for shareholders?
No. If a company raises money at a high share price and uses it to create value, such as funding a trial that succeeds, dilution can be rational. It becomes a problem when investors model upside using only market cap and ignore future share issuance. The key is to model the fully diluted share count, not just today’s market value.
What is the fully diluted share count?
The fully diluted share count includes common shares plus options, warrants, restricted stock units, convertible securities and other instruments that may convert into shares. It matters most when modeling buyout value per share, because a fixed acquisition price divided across more shares produces a lower value per share. Using only the basic share count can overstate per-share upside.
Bottom line
Dilution is not just an accounting detail. It directly affects per-share value. Do not model biotech upside using only market cap. Always model fully diluted share count.